15018752330
发表时间:2015-11-15 浏览次数:653次
Introduction
Gillan-Barre syndrome (GBS), which is also known as acute inflammatory
demyelinating polyradiculoneuropathy, is an autoimmune disease in which
the typical clinical symptoms are rapidly progressing symmetrical
weakness, areflexia and cerebrospinal fluid (CSF) protein levels
elevated without accompanying pleocytosis. It usually affects spinal
nerve roots especially the anterior roots, ganglions and peripheral
nerves, sometimes affects the cranial nerves.
According to its
clinical manifestation, laboratory examinations and
electro-physiological characteristics, GBS can be classified as acute
inflammatory demyelinating poly-neuropathy (AIDP), acute motor axonal
neuropathy (AMAN), acute motor sensory axonal neuropathy, Miller-Fisher
syndrome (MFS), acute autonomic neuropathy, and acute sensory
neuropathy. [1]
GBS is single-phase process and self-limiting, so most of the GBS
patients have a good prognosis, but some may have a bad prognosis
clinically. As the disease progresses, some of the AIDP patients may
turn into AMAN; some patients without obvious curative effect may
progress into chronic inflammatory demyelinating polyneuropathy; and
some patients may transform into relapsing GBS. Neural
electro-physiological examination, an irreplaceable auxiliary
examination for diagnosis of GBS, can provide an important basis for the
diagnosis and classification of the disease. In this study, the
clinical data of 338 GBS patients who were hospitalized during the
period of August 2008 to February 2013 were analyzed retrospectively.
Methods
Patients
This study retrospectively includes 338 GBS
patients who were hospitalized during the period of August 2008 to February
2013. All the cases were diagnosed under the diagnosis and treatment guidelines
of GBS published in 2010 by Chinese medicine association. Excluding 20 cases
without neural electro-physiological examination and 24 patients who were
diagnosed with MFS, 294 cases were included in this study eventually, with 186
male patients (63.3%) and 108 female patients (36.7%). Patient's ages ranged
from 4 to 82 years (mean 40.4 ± 18.3 years), and the average hospital stay was
18.8 days. There were precursor events emerging 1-4 weeks before in some of the
patients: respiratory infection or fever in 126 cases (42.9%), digestive tract
infection in 71 cases (24.1%), flu vaccination in 3 patients (1.0%), influenza
vaccination in 2 cases (0.7%), rabies vaccination in 2 cases (0.7%), pregnancy
in 1 case (0.3%), and the rest cases with no precursor events. The first symptom
was limb weakness in 276 cases (93.9%), sensory disturbance in 98 cases (33.3%),
and cranial nerve symptom in 54 cases (18.4%). There were 76 cases (25.9%) with
clinical symptoms of cranial nerve lesions, including 36 cases with facial nerve
paralysis, 8 cases with ophthalmoplegia, 7 cases with diplopia and 62 cases with
drinking water choking. There were 102 cases (34.7%) with clinical symptoms of
disturbance of sensation, 260 cases (88.4%) with upper-limb weakness, 276 cases
(93.9%) with lower limb weakness. There were 192 cases (65.3%) with tendon
hyporeflexia, 66 cases (22.4%) with disappearing and 11 cases (3.7%) with
hyperreflexia. 261 cases had a lumbar puncture while they were hospitalized, and
there were 205 cases (78.5%) with albumincytological dissociation. Two hundred
and eighteen cases had CSF immunoglobulin test, and there were 178 cases (81.7%)
with high levels of IgG, 36 cases (16.5%) with high levels of IgM, 137 cases
(62.8%) with high levels of IgA. The average time to disease peak period was 10
days; 65 cases (22.1%) suffered from the lung infection while 16 cases (5.4%)
suffered from urinary tract infection.
Electro-physiological
examination
Keypoint electromyography made by the Danish Dandi
Company was used. Since early stage of the disease, the electro-physiological
result showed abnormal F-wave only, and the result of nerve conduction showed
reduction of compound muscle action potential in most cases, so all patients
were performed at least one electro-physiological examination 2 weeks after the
onset of disease. Of the patients, 132 cases had their first
electro-physiological examination 2 weeks after the onset of disease and had
another check within 10-14 days after the first check: (1) All patients had
nerve conduction test by using surface electrodes to record and stimulate. We
detected motor conductive test on bilateral median nerve, ulnar nerve, peroneal
nerve, and tibial nerve recording the motor nerve conduction velocity, distal
latency, and amplitude, etc., and observed whether there was a nerve
conduction block (CB) or not. Sensory conduction test were performed at median
nerve, ulnar nerve, sural nerve, and phil shallow nerve recording the sensory
nerve conduction velocity; (2) all patients had F-wave detection on the median
nerve, ulnar nerve peroneal nerve and tibial nerve by recording the wave rate,
latency, etc.; (3) needle electromyography were performed on thenar
muscle, hypothenar muscle, deltoid, quadriceps, pretibial muscle, and
gastrocnemius by observing whether there was a spontaneous activity or not on
the resting moment and by testing the motor unit potential and recruitment order
of slight and strong muscle contraction.
Diagnostic and evaluation
criteria
(1) GBS and nerve block were diagnosed under the diagnosis
and treatment guidelines of GBS published in 2010 by Chinese Medicine
Association; (2) the neural electro-physiological types were classified into
AIDP and AMAN according to the electro-physiological diagnostic standard ] (3) normal patients and the patients not satisfying the
diagnostic criteria of AIDP and AMAN were included into the unclear type group;
(4) the disease classification and follow-up results were marked according to
rating scales designed by Hughes et al. Based on patients' ability
to walk with the help, patients were classified into mild type and serious type.
Patients with Hughes score equal or lesser than two points is the mild type, and
equal or more than three points is a serious type; (5) the prognostic
evaluations were marked according to rating scales designed by Hughes et al. Based on the patients' sequelaes (whether can walk without help or
not), patients were classified into favorable prognosis type and poor prognosis
type. Patients with Hughes score equal or lesser than two points is the
favorable prognosis type and equal or more than 3 points is the poor prognosis
type; (6) follow-up: 294 cases of GBS patients included in this study were
follow-up by telephone for 6 months after being discharged from hospital and 103
cases were lost to follow-up, so the response rate was 65.0%. Among the
remaining 191 cases, 3 died of non-GBS cause. There were 188 cases with
efficient results, which were included in this study eventually.
Statistical analysis
Data analysis was carried out using SPSS 17.0 Statistical Analysis
Software (Polar Enginneering and Consulting. http://www.winwrap.com/).
We compared clinical symptom, grading and prognosis between groups with
Chi-squared test, and considered statistical significance at P < 0.05.
Neural electro-physiological results
There were 102 cases (34.7%) in AIDP group and 81 cases (27.6%) in AMAN group . Based on the first electro-physiological testing, 132 patients were classified into: 58 cases (43.9%) of AIDP, 24 cases (18.2%) of AMAN, 50 cases (37.9%) of unclear . Cases belonged to AMAN group based on two different testing results were fewer than the cases in AIDP group and unclear classification cases group.
Relationship between early nerve conduction block and its electro-physiological changes
The first electro-physiological results for 132 cases with rechecks were: 58 cases (44%) in AIDP group, 24 cases (18%) in AMAN group, 50 cases (38%) in unclear classification group [Figure 3]. A total of 36 cases in AIDP group had CB, and cases transforming into AIDP and AMAN were 19 and 17, respectively.
Discussion
In this study, more male than female patients were included.
Respiratory tract and intestinal infections were the most common
precursor events. A few patients had influenza vaccine, H1N1 influenza
vaccine and rabies vaccine before the onset of the illness. It has been
reported that H1N1 vaccine maybe is a risk factor of GBS, but season
influenza vaccine was not related to it. [5],[6]
In our data, there is no evidence that H1N1 influenza vaccine was
related to GBS. The most common symptoms were symmetrical limb weakness
and numbness. Sensory disturbance is usually milder than motor
disturbance with reducing or disappearing tendon reflex. The common
cranial nerve damages are facial nerve paralysis, drinking water
choking, hoarseness, and ophthalmoplegial. All the cases were followed
by telephone for 6 months after hospital discharge. The response rate
was 65.0%. Twenty-one percent of the patients had serous sequel which
was the same as those reported in the literature. The mortality was
10.6% which was higher than previously reported. [6]
The most common subtypes of GBS are AIDP and AMAN with only motor fiber
damage. According to the literature, in North America and Europe more
than 90% of the patients is classified as AIDP, [4] but in China, the most common subtype is AMAN, and 65% of the GBS are AMAN. [7]
In this study, most cases among the 294 GBS patients were AIDP. Of
these, 132 cases were classified as AIDP based on their first
electro-physiological examination. These findings are in contrast with
what previously reported.
Because the classification based on
early stage GBS electro-physiological results is inaccurate,
electrophysiology testing was repeated after the illness developed and
the percentage of AIDP and AMAN cases changed comparing to the early
stage results. [8]
We classified patients into AIDP and AMAN groups and unclear
classification group which included patients whose electro-physiological
testing were normal and those who did not meet the diagnostic criteria
of AIDP and AMAN. We found that during disease progression
electro-physiological results, as well as the electro-physiological
classification, changed. The percentage of AMAN patients after recheck
increased significantly compared to the first check (from 18% to 41%),
which is the same as reported literature, [8],[9]
and AIDP reduced from 44% to 31%. We also found that AMAN had a worse
prognosis than AIDP, and this finding is consistent with the literature, [10],[11]
thus suggesting a poor prognosis in more patients. The classification
based on early stage GBS electrophysiologic results only may lead to
inaccurate judgment of the patients' diagnosis and prognosis, instead
continuous electrophysiology recheck can reflect the change of patient's
condition without delay.
Among the patients transforming from
AIDP into AMAN, CB occurred in 17 cases in the early onset of the
illness: 5 and 7 cases in AMAN and unclear classification group,
respectively. CB is a blockage in a nerve that prevents impulses from
being conducted across a given segment although the nerve beyond is
viable and is one of the important electro-physiological parameters of
peripheral nerve functional status. CB is one of the physiological
results caused by demyelination and is also the basic physiological
mechanism of most clinical manifestations. [12]
Most studies of CB published before are on multifocal motor neuropathy
and amyotrophic lateral sclerosis, peroneal muscular atrophy and
peripheral neuropathy caused by pressure. [13]
Though conventional wisdom holds that the main cause of CB is
demyelination and CB is the typical characteristics of demyelinating,
recent studies demonstrated that demyelination is not the only reason
for CB. It can caused by demyelination, depolarization on node of
ranvier nearby axolemma, hyperpolarization and sodium channel damage. [14]
The damage of nearby axolemma may cause CB, electro-physiological
manifest as decreased amplitude, discretized waveform. If the illness
continues to progress, reversible CB will turn into irreversible CB, and
axonal degeneration. This might explain why some of the CB cases
transformed into AMAN in electro-physiological classification.
Our
study demonstrated that CB not only occurred in AIDP patients, but also
in AMAN and unclear classification patients. In recent years, other
groups found that CB plays an important role in axon damaged AMAN. [15],[16] Kuwabara et al. [17]
thought that the possible cause of CB in AMAN was axonal degeneration.
The bridge type union of GM-1 antibody-mediated inflammatory cells and
axons, the release of inflammatory mediators, local acidosis, damage on
sodium ion channel of Axonal membrane and tight junction of axon myelin
(some authors believe that this is a different type of demyelination
from AIDP) resulted in a further decline of the safety factors,
eventually leading to CB. [18]
Our results suggested that the severity of the illness was related to
the development of CB in early stage in AIDP group and unclear
classification group but in the AMAN group is limited by small sample
size. As mentioned previously, damage factors of the axonal membrane may
the cause of CB, and then reversible CB will turn into irreversible CB
and axonal degeneration. According to the report of Kokubun et al. [9]
, the proportion of the two outcomes is 1:1 on AMAN patients who had
CB. Patients in this group with CB in early stage were not related to
the severity of the illness may be because some patients had reversible
CB. In addition, the use of immunoglobulin in early stage of disease in
patients with serious conditions may improve the prognosis and the
finding that development into CB in early stage correlates with the
severity of the illness might be another factor.
Due to the
objective condition limit that our patients mostly come from surrounding
cities and counties, and even other provinces, it is difficult to
diagnose these patients' neurological recovery face-to-face after they
are discharged from our hospital. We have to perform telephone follow-up
for most of them. At the same time, many patients filled temporary
numbers in the contact information form when hospitalized, which were no
longer used after they went back. This also limited the follow-up
results, and the response rate was only 65%. Furthermore, through
telephone follow-up, we can't evaluate the neural function of patients
completely and clearly. We will try to improve this in future work and
research.
In conclusion, reversible CB might be the cause of
changes in patients' electro-physiological classification. CB is not
only a typical electro-physiological manifestation in AIDP, but also a
manifestation of axonal degeneration for AMAN in the early stage. CB and
axonal degeneration are caused by immune-mediated damage factors which
attack axon membrane on the motor fiber. To a certain extent, CB is very
helpful in classifying the severity of the illness.
Electrophysiology recheck can be very meaningful to reveal change of
patient's condition, classification alteration and severity of the nerve
damage in time.
References
1.Dang JX. Electromyography Diagnosis and Clinical Applications. Beijing: People's Medical Publishing House; 2005.
2.Cui LY. Electromyography Condensed Handbook. Beijing: science Press; 2008.
3.Zhang KL, Xu JG. Clinical Utility of Electromyography Diagnosis Technology. Shanghai: fudan University Press; 2005.
4.Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-8.
5.Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10:643-51.
6.Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304.
7.Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
8.Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157-63.
9.Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain 2010;133:2897-908.
10.Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology 2003;61:471-4.
11.Brown WF, Feasby TE, Hahn AF. Electrophysiological changes in the acute "axonal" form of Guillain-Barre syndrome. Muscle Nerve 1993;16:200-5.
12.Liu T, Lu ZN. Demyelinating neuropathy physiological basis of conduction block. Str Nerv Dis 2006;13:59.
13.Ghosh A, Donaghy M. Multifocal motor neuropathy. Neurol India 2002;50:408-16.
14.Tang XF. Current insights into nerve block. Chin J Neuo 2003;36:404.
15.Kokubun N, Shahrizaila N, Hirata K, Yuki N. Conduction block and axonal degeneration co-occurring in a patient with axonal Guillain-Barré syndrome. J Neurol Sci 2012;319:164-7.
16.Raguer N, Gratacós M, Lladó E, Lara N, Seoane JL, Benito M, Rio J, Gámez J. Acute motor axonal neuropathy (AMAN), description of neurophysiological findings in 8 patients with early nerve conduction blocks. Clin Neurophysiol 2006;117:1-2.
17.Kuwabara S, Bostock H, Ogawara K, Sung JY, Kanai K, Mori M, Hattori T, Burke D. The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve 2003;28:683-9.
18.Wang RB, Liu XZ. Nerve conduction block and its mechanism. J Brain Nerv Dis 2006;14:239.